Breaking Down Shenzhen Weiguang Biological Products Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Shenzhen Weiguang Biological Products (002880.SZ) is a buy, sell or hold? The company reported CNY 1.20 billion in revenue for 2024, up 14.75% from CNY 1.05 billion, with TTM revenue at CNY 1.14 billion and revenue per share of CNY 6.59; market cap sits near CNY 5.80 billion (P/S 5.16) while the 52-week range is CNY 25.36-33.56 and beta is 0.24. Profitability shows net income of CNY 253.52 million in 2024 (+15.95% YoY), TTM net income CNY 228.68 million (EPS CNY 1.01), a net profit margin of 21.07%, ROE 10.12%, gross margin 42.38% and operating margin 25.30%. On the balance sheet the company carries total debt of CNY 669.5 million vs. equity of CNY 2.36 billion (book value per share CNY 10.25), debt/equity 28.8%, interest coverage 24.7 and net cash per share of CNY -2.68; total assets are CNY 3.3 billion with liabilities of CNY 1.0 billion. Liquidity and cash flow reveal a current ratio of 2.92 but a quick ratio of 0.79, operating cash flow of CNY 167.91 million, capex CNY 196.65 million, free cash flow of CNY -28.74 million and an Altman Z‑Score of 5.26. Valuation metrics include TTM P/E 25.83 (forward P/E 21.88), P/B 2.51, EV CNY 6.55 billion (EV/EBITDA 15.32, EV/FCF -227.72) and P/OCF 35.17. Key risks include regulatory pressures, a negative net cash position and negative FCF, while growth drivers point to forecasted annual earnings and revenue growth of 17.4% and 13.9% respectively, international sales ≈25% of revenue, and a projected ROE of 11.5% in three years-dive into the full analysis for the detailed implications of these figures.

Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Revenue Analysis

• 2024 revenue: CNY 1.20 billion (+14.75% year-over-year)
• 2023 revenue: CNY 1.05 billion
• TTM revenue: CNY 1.14 billion
• Latest quarter revenue per share: CNY 6.59

• The 14.75% revenue growth in 2024 demonstrates solid top-line momentum year-over-year.
• The TTM decline to CNY 1.14 billion versus 2024's CNY 1.20 billion signals near-term softening in sales - monitor upcoming quarterly trends for confirmation.
• A revenue-per-share of CNY 6.59 helps contextualize per-share sales productivity relative to share count and profitability metrics.
• With a market cap of ~CNY 5.80 billion and a P/S of 5.16, the market is valuing the company at a premium to revenue; investors should weigh margin profiles and growth prospects against that multiple.
• The 52-week range (CNY 25.36-33.56) and low beta (0.24) indicate limited market volatility historically despite price movement within that band.

Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Profitability Metrics

• 2024 net income: CNY 253.52 million (up 15.95% from CNY 218.68 million in 2023)
• Trailing twelve months (TTM) net income: CNY 228.68 million; TTM EPS: CNY 1.01
• Net profit margin: ~21.07%
• Return on equity (ROE): 10.12%
• Gross profit margin: 42.38%
• Operating margin: 25.30%

• Margin profile: The 42.38% gross margin and 25.30% operating margin create a wide operating spread that supports the 21.07% net margin, highlighting both production efficiency and disciplined operating cost control.
• Profit growth: A 15.95% increase in annual net income to CNY 253.52M underscores positive demand or price/mix improvements and/or better cost leverage.
• Capital efficiency: ROE of 10.12% signals moderate effectiveness in converting equity into profit; paired with solid margins, this suggests steady shareholder value creation.

Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Debt vs. Equity Structure

• Total debt: CNY 669.5 million
• Total assets: CNY 3.3 billion
• Total liabilities: CNY 1.0 billion
• Equity (book value): CNY 2.36 billion
• Book value per share: CNY 10.25
• Debt-to-equity ratio: 28.8%
• Debt-to-assets ratio: ~30.3%
• Interest coverage ratio: 24.7
• Net cash per share: CNY -2.68

Key takeaways for investors include a moderate leverage profile (debt-to-equity 28.8%) combined with strong interest coverage (24.7), meaning the company can comfortably service interest expenses, while the negative net cash per share and absolute debt level (CNY 669.5M) imply dependency on debt funding for part of operations and growth. For broader context on the company's background and strategy, see: Shenzhen Weiguang Biological Products Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Liquidity and Solvency

• Current ratio: 2.92 - ample short-term asset coverage of current liabilities.
• Quick ratio: 0.79 - below 1.0, indicating limited immediate liquidity without relying on inventory conversion.
• Operating cash flow: CNY 167.91 million - solid cash generated from core operations.
• Capital expenditures (CapEx): CNY 196.65 million - ongoing investment in production capacity and fixed assets.
• Free cash flow (FCF): CNY -28.74 million - CapEx exceeds operating cash generation this period.
• Altman Z-Score: 5.26 - suggests low bankruptcy risk and healthy solvency by common benchmarking.

• Liquidity nuance: the high current ratio implies sufficient current assets, but the sub-1 quick ratio signals reliance on inventory or slower-converting assets to meet immediate obligations.
• Cash flow trade-off: positive operating cash flow of CNY 167.91 million supports operations, yet aggressive CapEx of CNY 196.65 million drives free cash flow negative by CNY 28.74 million in the period.
• Solvency strength: an Altman Z-Score of 5.26 provides comfort on longer-term financial stability despite short-term cash timing mismatches.

Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Valuation Analysis

Key valuation metrics for Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) provide a snapshot of how the market prices its earnings, assets, sales and cash flows. Below are the current headline figures and interpretations tied directly to investor considerations.

• TTM P/E: 25.83 - implies investors currently pay CNY 25.83 for each CNY 1 of trailing earnings.
• Forward P/E: 21.88 - market expects earnings to increase, lowering the P/E if projections hold.
• P/B: 2.51 - equity valued at 2.51x book, indicating a premium over net asset value.

Interpretive notes for investors:

• Growth expectation: Forward P/E (21.88) below TTM P/E (25.83) signals anticipated earnings improvement - quantify by comparing consensus EPS growth rates to justify the multiple contraction.
• Asset premium: P/B of 2.51 indicates investors pay a premium for intangibles, brand, or expected returns on invested capital versus book assets.
• Profitability vs. valuation: EV/EBITDA of 15.32 situates the company at a moderately high valuation relative to operating earnings - assess against biotech/biopharma peers for context.
• Cash flow risk: EV/FCF of -227.72 and P/OCF of 35.17 point to weak or negative free cash flow and stretched operating cash conversion; monitor capex, working capital, and one-off items that drive FCF negative.
• Revenue pricing: P/S of 5.16 shows the market assigns a substantial premium per unit of revenue - check revenue growth sustainability and margin trends to substantiate this premium.

Valuation sensitivity checklist:

• Projected EPS growth vs. implied forward P/E - stress-test scenarios (base, upside, downside).
• Free cash flow trajectory and break-even timeline to move EV/FCF from negative toward positive.
• Relative multiples vs. domestic peer group and global biopharma benchmarks.
• Balance sheet strength given P/B and potential dilution or capital raises if cash flows remain negative.

For additional background on the company's history, ownership, mission and business model, see: Shenzhen Weiguang Biological Products Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Risk Factors

• Regulatory concentration: The company operates in biologics and plasma-derived products, a sector subject to strict regulatory oversight (production licenses, GMP audits, pricing controls). Regulatory delays or increased compliance costs can materially affect operations and time-to-market.
• Leverage and liquidity mismatch: Total interest-bearing debt materially exceeds cash reserves, increasing liquidity risk if operating performance weakens or refinancing conditions tighten.
• Negative free cash flow: Current capital expenditures outpace operating cash generation, pressuring financial flexibility and potentially increasing dependence on external financing.
• Low market sensitivity: A beta of 0.24 points to notably lower volatility vs. the broader market, which can dampen upside in bull markets and limit market-driven repricing.
• Net cash deficit: A negative net cash position indicates reliance on debt financing; rising interest rates or operational disruption could raise financing costs and stress covenants.
• Short-term coverage: A quick ratio of 0.79 suggests difficulty covering near-term liabilities without converting inventory to cash, exposing the company to working-capital strain.

• Immediate implications for investors:
  • Refinancing risk: With net leverage and negative FCF, upcoming maturities and covenant tests are focal points.
  • Operational sensitivity: Any regulatory rectification or production disruption could rapidly worsen cash flow and liquidity metrics.
  • Valuation interplay: Low beta may compress market-driven re-rating; fundamental improvements (margin expansion, FCF recovery) are likely required to materially change investor sentiment.

Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ) - Growth Opportunities

• Forecast annualized earnings growth: 17.4%
• Forecast annualized revenue growth: 13.9%
• Return on equity (ROE) forecast in three years: 11.5%
• International sales share of total revenues: ≈25%

• R&D and product pipeline: Continued investment in vaccine technology and diagnostic solutions is likely to translate into new revenue streams and higher-margin products over time.
• Global expansion: With roughly one-quarter of sales from overseas markets, incremental market penetration in Asia, Africa, and Latin America could materially boost revenue growth above domestic trends.
• Scale and margins: Strategic investments in production capacity and operational efficiencies are positioned to improve gross and operating margins as utilization rises.
• Brand & market position: Established brand loyalty in core product lines supports cross-selling and faster adoption of new offerings, aiding both volume growth and pricing power.